How Can Signal Interference Be Targeted in Cancer Therapy?
Targeting disrupted signaling pathways is a promising approach in cancer therapy. Strategies include:
1. Tyrosine Kinase Inhibitors (TKIs): Drugs like imatinib and erlotinib target specific tyrosine kinases involved in cancer signaling. 2. Monoclonal Antibodies: Antibodies such as trastuzumab target overexpressed receptors like HER2/neu. 3. Small Molecule Inhibitors: These inhibitors target specific components of signaling pathways, such as vemurafenib for mutant BRAF. 4. Immune Checkpoint Inhibitors: Drugs like pembrolizumab target immune checkpoints to enhance the body's immune response against cancer cells.
